



(51) International Patent Classification:

A61K 9/00 (2006.01) A61K 47/36 (2006.01)
A61K 31/715 (2006.01)

(21) International Application Number:

PCT/US2013/021903

(22) International Filing Date:

17 January 2013 (17.01.2013)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/588,783 20 January 2012 (20.01.2012) US

(71) Applicant: IMMUNOPHOTONICS, INC. [US/US];
4320 Forest Park Ave., #303 (BAL), St. Louis, MO 63108,
(US).

(72) Inventors: HODE, Tomas; Columbia, MO 65211 (US).
NORDQUIST, Robert; Oklahoma City, OK (US).
CHEN, Wei; Edmond, OK (US). CARUBELLI, Raoul;
Oklahoma City, OK (US). ALLERUZZO, Luciano;
Columbia, MO (US). JENKINS, Peter; Charlotte, NC
(US). WAYNANT, Kristopher; Champaign, IL (US).
RAKER, Joseph; Albany, NY (US).

(74) Agent: BROWN, Dennis D.; Brown Patent Law, P.L.L.C.,
2700 N. Hemlock Ct, Suite 111 E, Broken Arrow, OK
74012 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY,
BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP,
KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI,
NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU,
RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ,
TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA,
ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(88) Date of publication of the international search report:

8 January 2015

(54) Title: CHITOSAN-DERIVED COMPOSITIONS

(57) Abstract: Therapeutic compositions comprising chitosan-derived compositions used in connection with methods for treating neoplasms, such as for instance, malignant lung, thyroid and kidney neoplasms, and other types of malignant neoplasms, and other medical disorders. Glycated chitosan is a product of the glycation (non-enzymatic glycosylation) of free amino groups of chitosan, followed by stabilization by reduction. Glycation endows the chitosan with advantageous solubility and viscosity characteristics which facilitate the use of the derivative in conjunction with laser-assisted immunotherapy and other applications of the derivative. The glycation of chitosan also renders the chitosan more hydrophilic whereby more water is absorbed and retained by the polymer than would otherwise be the case.

